You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
18 search results for: barrier dysfunction
videoanimation
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?
Dermatology
Watch this short video to learn how type 2 inflammation, skin barrierdysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
Is Pediatric AD Linked to Other Allergic Diseases?
Dermatology
In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrierdysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.